JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

Search

Twist Bioscience Corp

Abrir

SetorSaúde

58.01 0.94

Visão Geral

Variação de preço das ações

24h

Atual

Mín

55.97

Máximo

58.45

Indicadores-chave

By Trading Economics

Rendimento

-3.4M

-31M

Vendas

4.7M

104M

Margem de lucro

-29.419

Funcionários

979

EBITDA

-3.2M

-24M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

-7.35% downside

Dividendos

By Dow Jones

Próximos Ganhos

4 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

1.1B

3.7B

Abertura anterior

57.07

Fecho anterior

58.01

Sentimento de Notícias

By Acuity

50%

50%

201 / 348 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Twist Bioscience Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

29 de abr. de 2026, 23:53 UTC

Ganhos

Naver Posts Weaker First-Quarter Earnings

29 de abr. de 2026, 23:41 UTC

Ações em Alta

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29 de abr. de 2026, 23:55 UTC

Ganhos

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29 de abr. de 2026, 23:54 UTC

Ganhos

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29 de abr. de 2026, 23:52 UTC

Ganhos

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29 de abr. de 2026, 23:51 UTC

Ganhos

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29 de abr. de 2026, 23:51 UTC

Conversa de Mercado

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29 de abr. de 2026, 23:34 UTC

Conversa de Mercado

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29 de abr. de 2026, 23:24 UTC

Ganhos

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29 de abr. de 2026, 23:24 UTC

Ganhos

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29 de abr. de 2026, 23:24 UTC

Ganhos

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29 de abr. de 2026, 23:24 UTC

Ganhos

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29 de abr. de 2026, 23:22 UTC

Ganhos

China Longyuan 1Q Net CNY1.70B, Down 14%

29 de abr. de 2026, 23:22 UTC

Ganhos

China Longyuan: Power Generation Down 2.9% as of End-March

29 de abr. de 2026, 23:20 UTC

Ganhos

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29 de abr. de 2026, 23:20 UTC

Ganhos

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29 de abr. de 2026, 23:19 UTC

Ganhos

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29 de abr. de 2026, 23:19 UTC

Ganhos

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29 de abr. de 2026, 23:19 UTC

Ganhos

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29 de abr. de 2026, 23:19 UTC

Ganhos

China Vanke 1Q Loss Narrows>000002.SZ

29 de abr. de 2026, 23:18 UTC

Ganhos

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29 de abr. de 2026, 23:17 UTC

Ganhos

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29 de abr. de 2026, 23:15 UTC

Ganhos

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29 de abr. de 2026, 23:15 UTC

Ganhos

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29 de abr. de 2026, 23:13 UTC

Ganhos

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29 de abr. de 2026, 23:12 UTC

Ganhos

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29 de abr. de 2026, 23:11 UTC

Ganhos

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29 de abr. de 2026, 23:11 UTC

Ganhos

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29 de abr. de 2026, 23:04 UTC

Ganhos

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29 de abr. de 2026, 23:04 UTC

Ganhos

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Comparação entre Pares

Variação de preço

Twist Bioscience Corp Previsão

Preço-alvo

By TipRanks

-7.35% parte inferior

Previsão para 12 meses

Média 54.8 USD  -7.35%

Máximo 58 USD

Mínimo 50 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Twist Bioscience Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

6

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

31.56 / 38.6884Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

201 / 348 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat